Karl D. Lewis - Concepedia

Author

Karl D. Lewis

University of Colorado Denver ORCID

Also Known As

K. D. Lewis, K. Lewis, K.D. Lewis, Karl D Lewis, Karl D. Lewis, Karl Lewis, Ken C. Lewis, Lewis, K.D., T. Jones

349

Publications

27.9K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver University of Colorado Cancer Center The University of Texas MD Anderson Cancer Center Moffitt Cancer Center Angeles Clinic and Research Institute

About

Karl D. Lewis is an author at University of Colorado Denver specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	73	9.7K
2	Health Sciences	16	24	3.1K
3	Cell Biology	8	8	704
4	Language Studies	1	1	13
5	Nursing	1	1	44

Karl D. Lewis

135

Publications

26.9K

Citations

H-Index

Page 1

	Year	Citations
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Keith T. Flaherty, J. Infante, Adil Daud, New England Journal of Medicine	2012	2.8K
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio, Journal of Clinical Oncology	2015	2.5K
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, New England Journal of Medicine	2012	2.1K
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Antoni Ribas, Igor Puzanov, Reinhard Dummer, The Lancet Oncology MedicineMelanomaImmunologyClinical TrialsImmune Checkpoint Inhibitor	2015	1.5K
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro, New England Journal of Medicine	2012	1.4K
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, New England Journal of Medicine	2018	1.3K
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi, New England Journal of Medicine	2018	1.3K
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, The Lancet Oncology MedicineMetronomic TherapyPathologyCancer TreatmentOncology	2016	1.2K
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, The Lancet MedicineMelanomaImmunologyPathologyPrimary Analysis	2020	631
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, The Lancet Oncology MedicineMelanomaPharmacologyImmune Checkpoint InhibitorPharmacotherapy	2012	534

Page 1